MedTrace Logo

Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy

NCT02338921 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2022-01-04

No results posted yet for this study

Summary

To assess the efficacy of treatment with sitagliptin or dapagliflozin or lobeglitazone in type 2 diabetes mellitus patients, who had inadequate glycemic control even though use of two drug combination therapy with glimepiride and metformin.

Conditions

Interventions

DRUG

Sitagliptin

100mg qd per oral during 24months compared with other treatment groups

DRUG

Dapagliflozin

10mg qd per oral during 24months compared with other treatment groups

DRUG

Lobeglitazone

0.5mg qd per oral during 24months compared with other treatment groups

DRUG

Glimepirde

DRUG

Metformin

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Principal Investigators

  • Soo Lim, MD, PHD · SNUBH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2021-11-30
Completion
2021-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02338921 on ClinicalTrials.gov